T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

Frohman, 2006, Multiple sclerosis – the plaque and its pathogenesis, N Engl J Med, 354, 942, 10.1056/NEJMra052130

Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7

McDonald, 1970, The effects of experimental demyelination on conduction in the central nervous system, Brain, 93, 583, 10.1093/brain/93.3.583

Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 899, 10.1056/NEJMoa044397

Stromnes, 2006, Active induction of experimental allergic encephalomyelitis, Nat Protoc, 1, 1810, 10.1038/nprot.2006.285

Furtado, 2008, Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis, J Immunol, 181, 4648, 10.4049/jimmunol.181.7.4648

O'Connor, 2008, Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis, J Immunol, 181, 3750, 10.4049/jimmunol.181.6.3750

Steinman, 1999, Assessment of animal models for MS and demyelinating disease in the design of rational therapy, Neuron, 24, 511, 10.1016/S0896-6273(00)81107-1

Stromnes, 2006, Passive induction of experimental allergic encephalomyelitis, Nat Protoc, 1, 1952, 10.1038/nprot.2006.284

Teitelbaum, 1971, Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, Eur J Immunol, 1, 242, 10.1002/eji.1830010406

Yednock, 1992, Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin, Nature, 356, 63, 10.1038/356063a0

Panitch, 1987, Exacerbations of multiple sclerosis in patients treated with gamma interferon, Lancet, 1, 893, 10.1016/S0140-6736(87)92863-7

Ferber, 1996, Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), J Immunol, 156, 5, 10.4049/jimmunol.156.1.5

Bettelli, 2004, Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis, J Exp Med, 200, 79, 10.1084/jem.20031819

Cua, 2003, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 421, 744, 10.1038/nature01355

Langrish, 2005, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J Exp Med, 201, 233, 10.1084/jem.20041257

Harrington, 2005, Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages, Nat Immunol, 6, 1123, 10.1038/ni1254

Mangan, 2006, Transforming growth factor-beta induces development of the T(H)17 lineage, Nature, 441, 231, 10.1038/nature04754

Das, 2009, Transforming growth factor {beta} is dispensable for the molecular orchestration of Th17 cell differentiation, J Exp Med, 206, 2407, 10.1084/jem.20082286

Sutton, 2006, A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis, J Exp Med, 203, 1685, 10.1084/jem.20060285

Yang, 2008, IL-21 and TGF-beta are required for differentiation of human T(H)17 cells, Nature, 454, 350, 10.1038/nature07021

Manel, 2008, The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat, Nat Immunol, 9, 641, 10.1038/ni.1610

Wilson, 2007, Development, cytokine profile and function of human interleukin 17-producing helper T cells, Nat Immunol, 8, 950, 10.1038/ni1497

Santarlasci, 2009, TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells, Eur J Immunol, 39, 207, 10.1002/eji.200838748

Hofstetter, 2005, Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis, Cell Immunol, 237, 123, 10.1016/j.cellimm.2005.11.002

Komiyama, 2006, IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis, J Immunol, 177, 566, 10.4049/jimmunol.177.1.566

Haak, 2009, IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice, J Clin Invest, 119, 61

Coquet, 2008, Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis, J Immunol, 180, 7097, 10.4049/jimmunol.180.11.7097

Kreymborg, 2007, IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis, J Immunol, 179, 8098, 10.4049/jimmunol.179.12.8098

Nowak, 2009, IL-9 as a mediator of Th17-driven inflammatory disease, J Exp Med, 206, 1653, 10.1084/jem.20090246

Lees, 2008, Host T cells are the main producers of IL-17 within the central nervous system during initiation of experimental autoimmune encephalomyelitis induced by adoptive transfer of Th1 cell lines, J Immunol, 180, 8066, 10.4049/jimmunol.180.12.8066

Kroenke, 2008, IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition, J Exp Med, 205, 1535, 10.1084/jem.20080159

Stromnes, 2008, Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells, Nat Med, 14, 337, 10.1038/nm1715

Abromson-Leeman, 2009, Encephalitogenic T cells that stably express both T-bet and RORgammat consistently produce IFNgamma but have a spectrum of IL-17 profiles, J Neuroimmunol, 215, 10, 10.1016/j.jneuroim.2009.07.007

Shi, 2008, Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells, J Immunol, 181, 7205, 10.4049/jimmunol.181.10.7205

Yang, 2009, T-bet is essential for encephalitogenicity of both Th1 and Th17 cells, J Exp Med, 206, 1549, 10.1084/jem.20082584

Gocke, 2007, T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity, J Immunol, 178, 1341, 10.4049/jimmunol.178.3.1341

Thakker, 2007, IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis, J Immunol, 178, 2589, 10.4049/jimmunol.178.4.2589

Gyulveszi, 2009, IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo, Eur J Immunol, 39, 1864, 10.1002/eji.200939305

Reboldi, 2009, C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE, Nat Immunol, 10, 514, 10.1038/ni.1716

Sallusto, 2009, Human Th17 cells in infection and autoimmunity, Microbes Infect, 11, 620, 10.1016/j.micinf.2009.04.004

Lock, 2002, Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nat Med, 8, 500, 10.1038/nm0502-500

Montes, 2009, Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells, Clin Immunol, 130, 133, 10.1016/j.clim.2008.08.030

Tzartos, 2008, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, Am J Pathol, 172, 146, 10.2353/ajpath.2008.070690

Matusevicius, 1999, Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis, Mult Scler, 5, 101, 10.1177/135245859900500206

Durelli, 2009, T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta, Ann Neurol, 65, 499, 10.1002/ana.21652

Frisullo, 2008, IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis, Cytokine, 44, 22, 10.1016/j.cyto.2008.08.007

Kebir, 2007, Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation, Nat Med, 13, 1173, 10.1038/nm1651

Kebir, 2009, Preferential recruitment of interferon-gamma-expressing T(H)17 cells in multiple sclerosis, Ann Neurol, 66, 390, 10.1002/ana.21748

Sawcer, 2005, A high-density screen for linkage in multiple sclerosis, Am J Hum Genet, 77, 454, 10.1086/444547

Friese, 2009, Pathogenic CD8(+) T cells in multiple sclerosis, Ann Neurol, 66, 132, 10.1002/ana.21744

Weiss, 2007, CD8+ T cells in inflammatory demyelinating disease, J Neuroimmunol, 191, 79, 10.1016/j.jneuroim.2007.09.011

Chen, 2009, Novel CD8(+) regulatory T cells suppress experimental autoimmune encephalomyelitis by TGF-beta- and IFN-gamma-dependent mechanisms, Eur J Immunol, 39, 3423, 10.1002/eji.200939441

Wucherpfennig, 1992, Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions, Proc Natl Acad Sci USA, 89, 4588, 10.1073/pnas.89.10.4588

Shimonkevitz, 1993, Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis, Proc Natl Acad Sci USA, 90, 923, 10.1073/pnas.90.3.923

Kobayashi, 1997, Aggravation of murine experimental allergic encephalomyelitis by administration of T-cell receptor gammadelta-specific antibody, J Neuroimmunol, 73, 169, 10.1016/S0165-5728(96)00187-7

Ponomarev, 2005, Gamma delta T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism, J Immunol, 174, 4678, 10.4049/jimmunol.174.8.4678

Ponomarev, 2004, Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis, J Immunol, 173, 1587, 10.4049/jimmunol.173.3.1587

Rajan, 1996, A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse, J Immunol, 157, 941, 10.4049/jimmunol.157.2.941

Rajan, 1998, The effect of gammadelta T cell depletion on cytokine gene expression in experimental allergic encephalomyelitis, J Immunol, 160, 5955, 10.4049/jimmunol.160.12.5955

Spahn, 1999, Decreased severity of myelin oligodendrocyte glycoprotein peptide 33-35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR delta chain gene, Eur J Immunol, 29, 4060, 10.1002/(SICI)1521-4141(199912)29:12<4060::AID-IMMU4060>3.0.CO;2-S

Odyniec, 2004, Gammadelta T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production, J Immunol, 173, 682, 10.4049/jimmunol.173.1.682

Cardona, 2002, Gamma/delta T cell-deficient mice exhibit reduced disease severity and decreased inflammatory response in the brain in murine neurocysticercosis, J Immunol, 169, 3163, 10.4049/jimmunol.169.6.3163

Koenecke, 2009, In vivo application of mAb directed against the gammadelta TCR does not deplete but generates ‘invisible’ gammadelta T cells, Eur J Immunol, 39, 372, 10.1002/eji.200838741

Lockhart, 2006, IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection, J Immunol, 177, 4662, 10.4049/jimmunol.177.7.4662

Shibata, 2007, Resident Vdelta1+ gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production, J Immunol, 178, 4466, 10.4049/jimmunol.178.7.4466

Sutton, 2009, Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity, Immunity, 31, 331, 10.1016/j.immuni.2009.08.001

Hori, 2004, Foxp3: a critical regulator of the development and function of regulatory T cells, Microbes Infect, 6, 745, 10.1016/j.micinf.2004.02.020

Fontenot, 2003, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells, Nat Immunol, 4, 330, 10.1038/ni904

Sakaguchi, 1995, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J Immunol, 155, 1151, 10.4049/jimmunol.155.3.1151

Roncarolo, 2006, Interleukin-10-secreting type 1 regulatory T cells in rodents and humans, Immunol Rev, 212, 28, 10.1111/j.0105-2896.2006.00420.x

Liston, 2007, Thymic development and peripheral homeostasis of regulatory T cells, Curr Opin Immunol, 19, 176, 10.1016/j.coi.2007.02.005

Curotto de Lafaille, 2009, Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?, Immunity, 30, 626, 10.1016/j.immuni.2009.05.002

Liu, 2006, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells, J Exp Med, 203, 1701, 10.1084/jem.20060772

Martinez-Forero, 2008, IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis, Eur J Immunol, 38, 576, 10.1002/eji.200737271

Astier, 2006, Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis, J Clin Invest, 116, 3252, 10.1172/JCI29251

Venken, 2008, Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level, Immunology, 123, 79, 10.1111/j.1365-2567.2007.02690.x

Feger, 2007, Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients, Clin Exp Immunol, 147, 412, 10.1111/j.1365-2249.2006.03271.x

Haas, 2005, Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis, Eur J Immunol, 35, 3343, 10.1002/eji.200526065

Venken, 2006, Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression, J Neurosci Res, 83, 1432, 10.1002/jnr.20852

Viglietta, 2004, Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis, J Exp Med, 199, 971, 10.1084/jem.20031579

Tsaknaridis, 2003, Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity, J Neurosci Res, 74, 296, 10.1002/jnr.10766

Huan, 2005, Decreased FOXP3 levels in multiple sclerosis patients, J Neurosci Res, 81, 45, 10.1002/jnr.20522

Frisullo, 2008, Regulatory T cells fail to suppress CD4(+)T-bet(+) T cells in relapsing multiple sclerosis patients, Immunology, 127, 418, 10.1111/j.1365-2567.2008.02963.x

Venken, 2007, A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses, J Immunol Methods, 322, 1, 10.1016/j.jim.2007.01.025

De Andres, 2007, Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis, J Neuroimmunol, 182, 204, 10.1016/j.jneuroim.2006.09.012

Kumar, 2006, CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis, J Neuroimmunol, 180, 178, 10.1016/j.jneuroim.2006.08.003

Korporal, 2008, Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells, Arch Neurol, 65, 1434, 10.1001/archneur.65.11.1434

Hong, 2005, Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3, Proc Natl Acad Sci USA, 102, 6449, 10.1073/pnas.0502187102

Xu, 2009, Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis, Clin Exp Immunol, 158, 26, 10.1111/j.1365-2249.2009.03987.x

Michel, 2008, Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis, J Clin Invest, 118, 3411

Fletcher, 2009, CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis, J Immunol, 183, 7602, 10.4049/jimmunol.0901881

Lafaille, 1994, High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice, Cell, 78, 399, 10.1016/0092-8674(94)90419-7

Olivares-Villagomez, 1998, Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis, J Exp Med, 188, 1883, 10.1084/jem.188.10.1883

Kohm, 2002, Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis, J Immunol, 169, 4712, 10.4049/jimmunol.169.9.4712

Zhang, 2004, IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells, Int Immunol, 16, 249, 10.1093/intimm/dxh029

Walsh, 2009, Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses, J Immunol, 183, 1577, 10.4049/jimmunol.0803803

Reddy, 2004, Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis, Proc Natl Acad Sci USA, 101, 15434, 10.1073/pnas.0404444101

Stephens, 2005, CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity, Proc Natl Acad Sci USA, 102, 17418, 10.1073/pnas.0507454102

Korn, 2007, Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation, Nat Med, 13, 423, 10.1038/nm1564

Liu, 2006, Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE, Nat Med, 12, 518, 10.1038/nm1402

McGeachy, 2005, Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system, J Immunol, 175, 3025, 10.4049/jimmunol.175.5.3025

Zhang, 2006, Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells, Int Immunol, 18, 495, 10.1093/intimm/dxh390

O'Connor, 2007, The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells, J Immunol, 179, 958, 10.4049/jimmunol.179.2.958

Cox, 2005, Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis, Eur J Immunol, 35, 3332, 10.1002/eji.200535075

Coles, 2008, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, N Engl J Med, 359, 1786, 10.1056/NEJMoa0802670

Stephens, 2009, Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg, Eur J Immunol, 39, 1108, 10.1002/eji.200839073

Lima, 2009, Briakinumab, Exp Opin Biol Ther, 9, 1107, 10.1517/14712590903092188

Melnikova, 2009, Psoriasis market, Nat Rev Drug Discov, 8, 767, 10.1038/nrd2996

Van Den Berg, 2009, IL-17 as a future therapeutic target for rheumatoid arthritis, Nat Rev Rheumatol, 5, 549, 10.1038/nrrheum.2009.179

Segal, 2008, Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study, Lancet Neurol, 7, 796, 10.1016/S1474-4422(08)70173-X

Longbrake, 2009, Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?, Expert Rev Neurother, 9, 319, 10.1586/14737175.9.3.319

Mills, 2008, Induction, function and regulation of IL-17-producing T cells, Eur J Immunol, 38, 2636, 10.1002/eji.200838535

Chen, 2006, Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis, J Clin Invest, 116, 1317, 10.1172/JCI25308

Eugster, 1998, IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis, Eur J Immunol, 28, 2178, 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D

Korn, 2008, IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells, Proc Natl Acad Sci USA, 105, 18460, 10.1073/pnas.0809850105

Kleinschek, 2007, IL-25 regulates Th17 function in autoimmune inflammation, J Exp Med, 204, 161, 10.1084/jem.20061738